Last reviewed · How we verify
Protopic - Tacrolimus 0.1%
At a glance
| Generic name | Protopic - Tacrolimus 0.1% |
|---|---|
| Sponsor | Sun Pharmaceutical Industries, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile (PHASE2, PHASE3)
- Comparative Evaluation of the Safety and Effectiveness of Crisaborole Ointment (2%) Versus Tacrolimus Ointment (0.1%) for the Topical Treatment of Atopic Dermatitis (PHASE4)
- Advancing Transplantation Outcomes in Children (PHASE2)
- Nevus Removal vs. Conservative Treatment in Halo Nevus With Vitiligo: A Randomized Study (NA)
- The Efficacy of Selenium as an Alternative or Complementary Topical Treatment of Oral Lichen Planus (PHASE4)
- Simulect Versus ATG in Sensitized Renal Transplant Patient (PHASE4)
- Photobiomodulation in Combination With Topical Cyclosporine A or Tacrolimus (EARLY_PHASE1)
- Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |